Going Global: Insights on the Advantages of Biotech Globalization Published in Drug Discovery Today from HiFiBiO Therapeutics Mar 6, 2023 By Vincent Tse
Mar 6, 2023 By Vincent Tse Going Global: Insights on the Advantages of Biotech Globalization Published in Drug Discovery Today from HiFiBiO Therapeutics
Jan 6, 2023 By Vincent Tse HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200603
Jan 5, 2023 By Vincent Tse HiFiBiO Therapeutics CEO Liang Schweizer Interviewed by Life Science Success Podcast
Nov 18, 2022 By sarahjibrin HiFiBiO Therapeutics Announces Clinical Trial Supply Agreement to Evaluate HFB200603 in Combination with Tislelizumab in Patients with DIS™ Selected Advanced Solid Tumors
Sep 5, 2022 By jeromer HiFiBiO Therapeutics to Present Trial in Progress Poster for HFB301001 at 2022 ESMO Congress
Aug 15, 2022 By Rick Bowen HiFiBiO Therapeutics Announces Clinical Trial Supply Agreement to Evaluate HFB200301 in Combination with Tislelizumab in Patients with DIS® Selected Advanced Solid Tumors
May 9, 2022 By sarahjibrin Lynn Bodarky Joins HiFiBiO Therapeutics as SVP, Global Head of Business Development and Alliance Management
Apr 27, 2022 By sarahjibrin HiFiBiO Therapeutics to Present Trial in Progress Poster for HFB200301 at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Apr 18, 2022 By sarahjibrin HFB200603, a novel anti-BTLA monoclonal antibody that provides therapeutic potential for immune escape and synergizes with anti-PD-1 treatment
Apr 18, 2022 By sarahjibrin Targeting regulatory T cells with HFB101110, a novel anti-human CCR8 antibody for the treatment of solid tumors
